Oakwood Southshore Medical Center

5450 Fort Street Trenton, MI 48183-4625



734.671.3800

September 24, 2009

United States Nuclear Regulatory Commission Attention: Document Control Desk Washington, DC 20555-0001

Re: Oakwood Southshore Medical Center

License No. 21-16656-01

Inspection Report No. 03011427/2009-001

This letter is in response to a request for further information regarding specific actions taken to resolve a safety concern identified during the NRC inspection conducted on May 6 and 7, and June 10, 2009, and mentioned in paragraph 5 of the inspection report.

We have addressed the concern regarding the safety issue mentioned in the NRC's letter dated July 15, 2009. Procedures are in place (and these are on file for NRC review if needed) to verify that the preimplant written directive includes all the information required by 10 CFR 35.40. Specifically, the written directive will include the **patient's name**, **treatment site**, **the radionuclide**, **and dose** (with proper units). In addition, post-implant checks will once again verify the treatment site, the radionuclide, and that the dose (which for prostate treatments is D90: dose to 90% of the prostate volume) is at least equal to 80% of the prescribed dose. Post-implant documentation will also include the number of sources and the total radioactivity implanted.

We believe that these actions will resolve the safety issue, will promote improved safety awareness with staff, and support regulatory compliance.

If you have any further questions regarding this response, please contact: Davis Flood, Imaging/Cardiology Director 734-671-3874 floodl@oakwood.org

Sincerely,

Edith Hughes

President, Oakwood Southshore Medical Center

Copy to:

United States Nuclear Regulatory Commission Regional Administrator, Region III 2443 Warrenville Road, Suite 210 Lisle, Illinois 60532-4352

> IE07 R6N3